The disclosure relates to a medical material including a copolymer having a repeating unit (A) represented by the following formula (1): ##STR00001## wherein R.sup.11 is a hydrogen atom or a methyl group, Z is an oxygen atom or NH, R.sup.12 is a C.sub.1-6 alkylene group, R.sup.13 and R.sup.14 are each independently a C.sub.1-4 alkyl group, and R.sup.15 is a C.sub.1-6 alkylene group, and a repeating unit (B) represented by the following formula (2): ##STR00002## wherein R.sup.21 is a hydrogen atom or a methyl group, R.sup.22 is a C.sub.1-6 alkylene group, and R.sup.23 is a C.sub.1-4 alkyl group. The repeating unit (A) is contained in a proportion of 0.6 to 7 mol % based on all the structural units of the copolymer. The disclosure makes it possible to provide a medical material and a medical device, which exhibit excellent antithrombogenicity even when used under severe conditions prone to thrombus formation.

A thrombo-resistant catheter includes a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an intraluminal surface and an extraluminal surface, and the hydrogel coating is disposed on the intraluminal surface and/or the extraluminal surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt. % to about 1 wt. % tissue plasminogen activator. The hydrogel coating may be made of a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide-based hydrogels. Presently preferred natural hydrogels include hyaluronic acid-based hydrogels. The hydrogel coating reacts in the presence of a physiological fluid to absorb water and elute the thrombolytic agent. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluid include interstitial fluid and blood.

The present invention includes a catheter locking solution having both antimicrobial and anticoagulant properties including a local anesthetic and a viscosifying agent. The local anesthetic of the present invention may be an amino amide; an amino ester; an aminoacylanilide; an aminoalkyl benzoate; an amino carbonate; an N-phenylamidine compound; an N-aminoalkyl amid; an aminoketone, or combinations and mixtures thereof. In a particular embodiment of the present invention, the local anesthetic is tetracaine or dibucaine.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

An antithrombogenic material includes: a coating material containing a skeletal structure composed of a polymer, a skeletal structure composed of 4-(aminomethyl)benzenecarboxyimidamide or benzene amidine, and a skeletal structure composed of methoxybenzenesulfonic acid amide; and a base material whose surface is coated with the coating material; wherein the coating material is covalently bound to the base material, and the peak abundance ratio of the carbonyl-derived component in the total component of the C1s peak as measured by X-ray photoelectron spectroscopy on the surface is not less than 1.0 atomic percent.

A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.

The disclosure relates to a medical material including a copolymer having a repeating unit (A) represented by the following formula (1):

##STR00001## wherein R.sup.11 is a hydrogen atom or a methyl group, Z is an oxygen atom or NH, R.sup.12 is a C.sub.1-6 alkylene group, R.sup.13 and R.sup.14 are each independently a C.sub.1-4 alkyl group, and R.sup.15 is a C.sub.1-6 alkylene group, and a repeating unit (B) represented by the following formula (2):

##STR00002## wherein R.sup.21 is a hydrogen atom or a methyl group, R.sup.22 is a C.sub.1-6 alkylene group, and R.sup.23 is a C.sub.1-4 alkyl group. The repeating unit (A) is contained in a proportion of 0.6 to 7 mol % based on all the structural units of the copolymer. The disclosure makes it possible to provide a medical material and a medical device, which exhibit excellent antithrombogenicity even when used under severe conditions prone to thrombus formation.

Provided is a clot adhesion preventing agent capable of suppressing adhesion of clot to the inner wall surface of a blood collection container. The clot adhesion preventing agent according to the present invention includes a polyether compound or a silicone oil, and an amino acid.

A medical device, which includes: a base material; an antithrombogenic layer including a polymer fixed to the base material, in which the polymer includes: a structural unit a derived from a first monomer bonded to the base material and including a reactive group that reacts with a hydroxyl group or a carboxyl group and an ethylenically unsaturated group; a structural unit B including a polymer chain including a structural unit b derived from a first antithrombogenic monomer including a carboxyl group and an ethylenically unsaturated group, and including a terminal of the polymer chain bonded to the structural unit a; and a structural unit C derived from a copolymer including a structural unit c1 derived from a second monomer including an amino group and bonded to the structural unit b and a structural unit c2 derived from a second antithrombogenic monomer.